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Abstract 
Purpose: To evaluate the cardioprotective effects and possible mechanisms of Dan-Yang-Fu-Xin 
decoction (DYFX) in a rat chronic heart failure (CHF). 
Methods: A CHF rat model induced by ligation of the left anterior descending coronary artery was used 
to investigate the cardioprotective effects of DYFX. After intragastric administration for 8 weeks, several 
functional cardiac indices, including fractional shortening (FS), ejection fraction (EF), heart rate (HR) 
and cardiac output (CO) were assessed by ultrasound examination. Subsequently, inflammatory 
markers, viz, interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α), myocardial enzymes, namely, 
lactate dehydrogenase (LDH) and creatine kinase (CK), were also assessed by enzyme-linked 
immunosorbent assay (ELISA). 
Results: Intragastric administration of DYFX (200, 400 and 600 mg/kg) significantly reversed the 
decrease in body weight and increase in cardiac weight (p < 0.05) induced by CHF. Treatment with 
DYFX also significantly reversed EF, FS, HR, and CO changes in CHF rats. In addition, DYFX inhibited 
the two inflammatory cytokines (TNF-α and IL-6) and myocardial enzymes (CK and LDH), suggesting 
that these effects may include the mechanisms of cardioprotectiion involved in attenuation of CHF. 
Conclusion: DYFX possesses cardioprotective effects involving CHF. The protective mechanisms may 
include the suppression of expression of inflammatory mediators and myocardial enzymes. 
 
Keywords: Dan-Yang-Fu-Xin decoction, Cardioprotection, Chronic heart failure, Inflammatory 
mediators, Myocardial enzymes 
 
Tropical Journal  of Pharmaceutical Research is indexed by Science Citation Index (SciSearch), Scopus, 
International Pharmaceutical Abstract, Chemical Abstracts, Embase, Index Copernicus, EBSCO, African 
Index Medicus, JournalSeek, Journal Citation Reports/Science Edition, Directory of Open Access Journals 




Chronic heart failure (CHF) is a complex clinical 
syndrome involving impairment of cardiac pump 
function, resulting in a heart that cannot pump 
sufficient blood to meet the metabolic needs of 
the body [1,2]. CHF involves ventricular 
remodeling and hypertrophy, reduced cardiac 
ejection fractions (EFs) and impairment of active 
relaxation and contraction of the left ventricle [3]. 
CHF represents a major public health problem in 
the world because of its high morbidity, mortality 
and cost [4]. 
  
Currently, angiotensin receptor antagonists, β-
blockers, mineralocorticoid receptor blockers and 
diuretics have been used for treatment of CHF. 
However, these treatments are because of their 
side effects including damage to the liver, kidney, 
and gastrointestinal tract [5,6]. Traditional 
Chinese medicine (TCM) has shown efficacy in 
treating complex multi-factor diseases, because 
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TCM is a unique medical system that uses drugs 
with multiple components that have synergistic 
therapeutic efficacies [6-8]. Dan-Yang-Fu-Xin 
decoction (DYFX) is a TCM prescription 
consisting of Salvia miltiorrhiza, Epimedium 
brevicornu, Ligusticum wallichi, Astragalus 
membranaceus and Glycyrrhiza uralensis (Table 
1). 
 
It has been widely used in cities northern China, 
such as Linyi, Yanzhou and Tengzhou to treat 
coronary heart disease, anemia, chronic 
bronchitis and osteoporosis. DYFX is also 
beneficial for asthma and allergies. However, to 
the best of our knowledge, there have been no 
reports describing the pharmacological effects of 
DYFX. 
 
The aim of the present study was to investigate 
the cardioprotective effects of DYFX in a CHF rat 
model by determining several cardiac function 
indices as well as the relationship between DYFX 




Chemicals and reagents 
 
Interleukin-6 (IL-6) and tumor necrosis factor-α 
(TNF-α) enzyme-linked immunosorbent assay 
(ELISA) kits were purchased from Shanghai 
Bluegene Biotech (Shanghai, China). Creatine 
kinase (CK) and lactate dehydrogenase (LDH) 
ELISA kits were purchased from R&D systems 
(Beijing, China). Chloral hydrate was purchased 
from Kermel (Tianjin, China). All other chemicals 
and reagents used were of analytical grade. 
 
Preparation of DYFX water extracts 
 
Because DYFX is prepared by directly decocting 
with water in traditional folk medicine, all 
preparations of DYFX (Table 1) were in powder 
form and were soaked for 8 h before decocting 
with distilled water six times and extracted three 
times for 30 min each time. The decoction were 
filtered and concentrated under reduced 
pressure at 55 oC with a vacuum rotary 
evaporator. The resulting w/w yield of DYFX was 
11.2 %. Distilled water was used to dissolve and 
dilute the extract to the appropriate 
concentrations for intragastric administration. 
 
CHF animal model 
 
Male Sprague-Dawley rats weighing 220 ± 20 g 
were housed under controlled conditions at a 
temperature of 22 ± 1 °C and humidity of 45 ± 5 
% with a 12 h light/dark cycle. The rats had free 
access to standard pallet diet (solid rodent chow) 
and tap water. The experiments were performed 
after 1 week acclimatization period. The 
experimental procedures were approved by the 
Committee of Animal Care and Use of our 
institute. 
 
The rats were anaesthetized by intraperitoneal 
injection of chloral hydrate (300 mg/kg). 
Myocardial infarction and heart failure were 
induced by ligation of the left anterior descending 
coronary artery as previously described [9,10]. 
The surviving rats were randomly divided into 
five groups (n = 14): 1) the control group, 2) the 
CHF group, 3) the high dose DYFX group (600 
mg/kg/d), 4) the medium dose DYFX group (400 
mg/kg/d), 5) the low dose DYFX group (200 
mg/kg/d). The control group received the same 
surgery but without ligating the vessel. The 
treatment was continued for 8 weeks via 
intragastric administration. At the end of the 
procedure, cardiac function was examined, blood 
samples were drawn from the abdominal aorta, 
and the serum was stored at -80 °C.  
 
Determination of cardiac function 
 
Animals were anesthetized intraperitoneally with 
chloral hydrate (300 mg/kg). A portable 
ultrasound (Vivid I, GE Healthcare, Little 
Chalfont, UK) equipped with a 12-MHz linear 
transducer (12 L) was used to determine the 
fractional shortening(FS), ejection fraction (EF), 
heart rate (HR) and cardiac output (CO). An 
ultrasound image workstation (GE Healthcare) 
was used to transfer data online for subsequent 
analysis. 
 
Table 1: Composition of Dan-Yang-Fu-Xin Decoction (DYFX) 
 
Plant Plant part  Weight (g)                                                                                                                             
Salvia miltiorrhiza  Roots 40 
Epimedium brevicornu  Whole herbs 30 
Ligusticum wallichi  Roots 15 
Astragalus membranaceus Roots 10 
Glycyrrhiza uralensis Roots 5 
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Determination of TNF-α and IL-6  
 
The myocardial tissues were homogenized in 
RIPA lysis buffer containing 50 mM Tris-HCl 
(pH=7.4), 150 mM NaCl, 1 % Triton X-100, 1 % 
sodium deoxycholate, 0.1 % SDS, 1 mM 
Na3VO4, 1 mM EDTA, 1 mM 
phenylmethylsulfonyl fluoride and 1 mM NaF, 
(myocardial tissue - RIPA lysis buffer ratio was = 
1:10, v/v) and then centrifuged (6,000 × g, at 4 
°C for 15 min). The supernatants were collected 
to analyze TNF-α and IL-6 using ELISA kits 
according to the manufacturers’ instructions. 
 
Determination of serum LDH and CK  
 
Serum was separated from whole blood using 
centrifugation (6000 g, 4 oC and 15 min). Serum 
levels of LDH and CK were measured using 





Statistical analysis of data were performed using 
SPSS software, version 13.0 (SPSS, Chicago, 
IL, USA). All data are expressed as the mean ± 
SD. One-way ANOVA was used for statistical 
analyses of observed values. A value of p < 0.05 




Effects of DYFX on body weight and cardiac 
weight 
 
As shown in Table 2, the body weight of animals 
in the CHF group significantly decreased (p < 
0.05) compared with animals in control group. 
Furthermore, the whole heart weight, left 
ventricular weight, index of heart weight to body 
weight and index of left ventricle weight to body 
weight were significantly increased (p < 0.05) in 
CHF rats. However, intragastric administration of 
DYFX (200, 400, and 600 mg/kg) significantly 
reversed these changes (p < 0.05), indicating 
that DYFX could reduce cardiac hypertrophy in 
CHF animals (Table 2). 
 
Effect of DYFX on cardiac functions  
 
Figure 1A and 1B showed that the EF and FS of 
the CHF group significantly decreased (p < 0.05) 
compared with the control group. However, the 
EF in DYFX treated groups increased 
significantly (p < 0.05) compared with the CHF 
group, and the FS in the DYFX treated groups 
(400 mg/kg and 600 mg/kg, p < 0.05) 
significantly increased compared with the CHF 
group. HR and CO are shown in Figure 1C and 
1D. The HR and CO of CHF rats were 
significantly decreased compared with the control 
group (p < 0.05). However, the HR in the DYFX 
treated groups significantly increased (p < 0.05) 
compared with the CHF group, and the CO in the 
DYFX treated groups (400 mg/kg and 600 mg/kg, 
p < 0.05) significantly increased compared with 
the CHF group. Taken together, the results 
showed that DYFX significantly reversed EF, FS, 
HR and CO changes in CHF rats. 
 
Effect of DYFX on TNF-α and IL-6 levels  
 
Figure 2 shows that myocardial production of 
TNF-α and IL-6 increased significantly in the 
CHF group compared with the control group (p < 
0.01). The levels of the two cytokines decreased 
in groups treated with DYFX compared with the 
CHF group (200 mg/kg, p < 0.05; 400 mg/kg and 
600 mg/kg, p < 0.01, respectively). The results 
showed that there was a close relationship 
between CHF and inflammation, and treatment 
with the DYFX effectively inhibited expression of 
the two inflammatory cytokines induced by CHF. 
 
Effect of DYFX on LDH and CK 
 
Figure 3 shows that, there was a significant 
increase (p < 0.01) in serum LDH levels of the 
CHF group compared with the control group. 
Treatment with 400 mg/kg DYFX resulted in a 
significant decrease (p < 0.01) in serum LDH 
levels as compared with the CHF group, and a 
significant increase (p < 0.01) in serum CK levels 
in the CHF groups compared with Control group. 
Table 2: Effects of DYFX on body weight and cardiac weight 
 
Group Body weight (g) 
Whole heart  
weight (g) 
Left ventricular  
weight (g) 
Index of  
Heartweight to 
body weight 
Index of left 
Heartweight to 
body weight 
Control 289.26 ± 10.27 * 0.86 ± 0.09 * 0.55 ± 0.04 * 0.30 ± 0.03 * 0.19 ± 0.03 * 
CHF 268.75 ± 8.53 1.06 ± 0.10 0.78 ± 0.08 0.39 ± 0.04 0.29 ± 0.02 
200 279.32 ± 9.76 * 0.97 ± 0.09 0.63 ± 0.06 * 0.35 ± 0.03 0.23 ± 0.03 * 
400 284.72 ± 8.92 * 0.95 ± 0.08 * 0.59 ± 0.05 * 0.33 ± 0.03 * 0.21 ± 0.02 * 
600 283.91 ± 7.98 * 0.92 ± 0.07 * 0.58 ± 0.03 * 0.32 ± 0.02 * 0.20 ± 0.02 * 
Data were expressed as mean ± SD; *p < 0.05, compared with CHF group 
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Figure 1: Effects of DYFX on EF, FS, CO and HR of the CHF rats. Data were expressed as Mean ± SD;. *p < 
0.05, compared with CHF group 
 
 
Figure 2: Effect of DYFX on TNF-α, IL-6 in CHF rats. Data were expressed as Mean ± S.D.. *p < 0.05, compared 
with CHF group. **p < 0.01, compared with CHF group 
 
 
Figure 3: Effects of DYFX on CK and LDH in serum of CHF rats. Data were expressed as Mean ± SD; *p < 0.05, 
compared with CHF group; **p < 0.01, compared with CHF group 
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Treatment (200 mg/kg, p < 0.05; 400 mg/kg and 
600 mg/kg, p < 0.01) resulted in a significant 





In present study, a CHF rat model induced by 
ligation of the left anterior descending coronary 
artery was used to investigate the 
cardioprotective effects of DYFX. The results 
showed that DYFX reduced cardiac hypertrophy 
and reversed EF, FS, HR and CO changes in 
CHF rats. The possible mechanism of these 
cardioprotective effects might be related to the 
inhibition of inflammatory cytokine levels and 
myocardial enzymes levels. It is well-known that 
CHF is associated with immune activation, and 
its development and progression were closely 
related to inflammatory cytokines [11]. The 
overproduction of inflammatory factors, 
especially TNF-α and IL-6, could cause a 
decrease in cardiac systolic potential and cardiac 
output. The two factors could cause necrosis and 
apoptosis of cardiomyocytes and contribute to 
myocardial remodeling, resulting in worsening of 
CHF [5, 12]. The levels of TNF-α and IL-6 were 
evaluated in our study, showing that treatment 
with DYFX significantly suppressed the 
inflammation response via by decreasing the 
levels of TNF-α and IL-6 in CHF rats. 
 
CK and LDH are marker enzymes of cardiac 
damage. There have been many reports 
describing the relationship between the two 
myocardial enzymes and cardioprotective effects 
[13-15]. The CK and LDH are released into the 
blood stream after myocardial injury. These 
myocardial enzymes levels were determined in 
the serum of CHF rats in our study, showing that 




The present study shows that DYFX possesses 
potent cardioprotective effects on CHF animals. 
The protective mechanisms may involve 
suppression of the expressions of inflammatory 
mediators and myocardial enzymes. However, 
further investigations are required to identify the 
chemical constituents and complete mechanisms 
of DYFX action. 
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